Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE
about
Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE
description
clinical trial
@en
klinisch onderzoek
@nl
name
Sorafenib Plus Tegafur-uracil ...... for Local Ablation and/or TACE
@en
type
label
Sorafenib Plus Tegafur-uracil ...... for Local Ablation and/or TACE
@en
prefLabel
Sorafenib Plus Tegafur-uracil ...... for Local Ablation and/or TACE
@en
P1476
A Phase II Trial of Sorafenib ...... e for Local Ablation &/or TACE
@en
P17
P3098
NCT01539018
P580
2012-01-01T00:00:00Z
P582
2015-01-01T00:00:00Z